2nd Nov 2006 07:00
Vernalis PLC02 November 2006 2 November 2006 Vernalis to Present at Cowen and Company 7th Annual Global Health Care Conference WINNERSH, U.K., November 2, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), aspecialty bio-pharmaceutical and drug development company, today announced thatSimon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer,will participate in the Cowen and Company 7th Annual Global Health CareConference to be held November 7-8, 2006 at the Landmark Hotel in London. Mr.Sturge is scheduled to present an overview of the Company's business activitiesand product pipeline at 16:50 GMT on Wednesday, November 8, 2006. Investors may access a live webcast of the presentation at www.vernalis.comunder the Investor Relations tab. The presentation will be archived for 3months. About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. -- ends --Enquiries: Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy Lazar Partners LtdGregory Gin 212-867-1762 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC